Risk factors for hospitalization and death due to COVID-19 among frail community-dwelling elderly people: a retrospective cohort study.

Background: Advanced age, multiple chronic diseases and frailty have been correlated with worse prognosis among coronavirus disease 2019 (COVID-19) inpatients.

Objective: To investigate potential risk factors for hospitalization and death due to COVID-19 among frail community-dwelling elderly people.

Design And Setting: Retrospective cohort study of patients followed up at a geriatric outpatient clinic in Belo Horizonte, Minas Gerais, Brazil.

[Health behaviors and preventive tests in adults with and without health insurance in Greater Metropolitan Belo Horizonte, Minas Gerais State, Brazil, 2003-2010].

This study analyzed indicators for health behaviors and use of preventive services in two probabilistic samples of adults, one in 2003 (n = 13,757) and the other in 2010 (n = 12,983), with and without private health insurance in Greater Metropolitan Belo Horizonte, Minas Gerais State, Brazil. After adjusting for demographic variables, temporal variation, and source of care, there was a reduction in smoking prevalence, similar between individuals with and without private health insurance, from 2003 to 2010. During this same period the prevalence of excessive alcohol intake and sedentary lifestyle increased in both groups; with the same magnitude, there was a decrease in the prevalence of leisure-time physical activity.

[A population-based study on factors associated with performance on the Mini-Mental State Examination in the elderly: the Bambuí Study].

The aim of this study was to examine factors associated with cognitive functioning in community-dwelling older adults with low schooling. 1,588 subjects residing in Bambuí, Minas Gerais State, Brazil, and aged > 60 years participated in this cross-sectional study. Multivariate ordinal logistic regression was used to assess associations between exploratory variables and the Mini-Mental State Examination score (MMSE): < 13 (below the 5th percentile), 14-21 (between the 5th percentile and the lowest quintile), and > 22.

A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia.

Background/aims: To evaluate the efficacy and safety of venlafaxine in the treatment of major depression in dementia.

Methods: Thirty-one outpatients who had dementia and major depression participated in this randomized, double-blind, placebo-controlled, 6-week, flexible dose clinical trial. The screening measures were Cornell Scale for depression in dementia, DSM-IV for depression and dementia and Mini-Mental State Examination.